CLINIQUE MUTUALISTE DE L'ESTUAIRE

At CLINIQUE MUTUALISTE DE L'ESTUAIRE, the radiotherapy department conducts clinical research targeting cancers of the digestive tract, aiming to improve survival outcomes through innovative drug combinations.

• Colon cancer adjuvant therapy with Irinotecan and Oxaliplatin
• Metastatic esophagogastric adenocarcinoma treatment with trifluridine/tipiracil plus Fruquintinib
• Disease‑free survival as a primary endpoint
• Overall survival improvement strategies
• Combination chemotherapy approaches
• Targeted therapy integration

The site leverages its radiotherapy expertise to support multidisciplinary cancer care and advance therapeutic options for digestive system malignancies.

Research in the area of male urogenital oncology focuses on repurposing well‑known cardiovascular agents to extend life expectancy for patients with advanced prostate cancer.

• Aspirin and atorvastatin combination therapy
• Overall survival as the main study endpoint
• Castration‑resistant prostate cancer population
• Drug repurposing strategy
• Elderly patient considerations
• Integration with existing oncologic protocols

Collaboration between radiotherapy and medical oncology teams ensures comprehensive evaluation of systemic treatments at the site.

The department’s oncology portfolio includes trials that combine radiotherapy with novel systemic agents across several tumor types, seeking to enhance disease control and patient outcomes.

• Head and neck squamous cell carcinoma – radiotherapy plus cetuximab and Xevinapant
• Anal squamous cell carcinoma – induction chemotherapy followed by chemoradiotherapy
• ER‑positive HER2‑negative breast carcinoma in women over 70 – chemotherapy with or without hormonotherapy
• Progression‑free survival evaluation
• Disease‑free survival measurement
• Use of independent review committees for outcome assessment

The multidisciplinary approach at the site enables enrollment of diverse patient groups and thorough investigation of combined treatment modalities.

Beyond disease‑specific studies, the center monitors clinical outcomes and symptom management to capture the full impact of therapies on patients’ health.

• Disease‑free survival as a key metric
• Overall survival tracking across trials
• Progression‑free survival assessments
• Event‑free survival in high‑risk cohorts
• Independent review committee evaluations
• Genomic grade‑guided therapy decisions

Radiotherapy specialists work closely with pathology and imaging units to ensure accurate and comprehensive outcome measurement in all studies.